Abbott to market Zydus products in emerging markets by 2013

MUMBAI: Pharma major Abbott India, which has entered a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that the former will commercialize in 14 emerging markets, will commence operations in 2013, a top official said today.

"Our marketing alliance with Zydus Cadila will start by 2013. Abbott will gain rights to at least 25 products in 14 emerging markets," Abbott India's managing director Vivek Mohan told PTI here.

Last year, Abbott and Zydus Cadila entered into an agreement to market Zydus products, which includes indications for pain, cancer and cardiovascular, neurological and respiratory diseases.

Abbott has created the Established Products Division (EPD), dedicated to expanding the market for its established pharmaceutical portfolio outside of the US, with an emphasis on emerging markets.

Meanwhile, Abbott India, with over 100 years of operations in India, has invested over Rs 61 crore (USD 12 million) in grants, donations and social innovation projects in India, impacting the lives of over 15 lakh Indians.

The company employs more than 12,000 people in its two manufacturing facilities and two R&D centres in the country.

The company today released 'Redefining Responsibility' Citizenship Report 2011 for India. The report reflects the company's approach to citizenship in India. Working beyond philanthropy, Abbott applies its science, expertise and technology to address critical health care needs through innovative partnerships with governments, health-care professionals and NGOs.

Building on our significant outreach in 2011, Abbott plans to expand its efforts in India to deliver even stronger benefit for the people it serve in 2012.

It is planning to reach 10 lakh patients through thyroid and diabetes camps next year, Mohan said.

The company said it is working closely with the Ministry of Health and Family Welfare, Ministry of Consumer Affairs and the Ministry of Women and Child Development to advance the safety and quality standards pertaining to Food Laws. The company developed and launched valance solution, a flavored syrup-based preparation of Divalproex for epilepsy patients who cannot take tablets.